Stop-and-go oxaliplatin effective in elderly colon cancer patients
Elderly patients with metastatic colon cancer, those between 76 and 80 years of age, have response and survival rates similar to their younger counterparts when given a treatment approach that includes stop-and-go oxaliplatin.
Elderly patients with metastatic colon cancer are generally excluded from randomized clinical trials, but were included in the OPTIMOX1 trial, led by Dr. Arie Figer of Beth Sourasky Medical Center in Tel Aviv, Israel. OPTIMOX1 was an evaluation of FOLFOX7, a simplified leucovorin (LV) and 5-fluorouracil (5FU) regimen (sLV5FU2) with high-dose oxaliplatin, in a new oxaliplatin stop-and-go strategy.
Elderly patients with metastatic colon cancer, those between 76 and 80 years of age, have response and survival rates similar to their younger counterparts when given a treatment approach that includes stop-and-go oxaliplatin.
Elderly patients with metastatic colon cancer are generally excluded from randomized clinical trials, but were included in the OPTIMOX1 trial, led by Dr. Arie Figer of Beth Sourasky Medical Center in Tel Aviv, Israel. OPTIMOX1 was an evaluation of FOLFOX7, a simplified leucovorin (LV) and 5-fluorouracil (5FU) regimen (sLV5FU2) with high-dose oxaliplatin, in a new oxaliplatin stop-and-go strategy.